This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different
types of solid tumors. It will also find out what side effects may occur. A side effect is
anything the drug does besides treating cancer.
This trial is designed to assess the antitumor activity, safety, and tolerability of LV for
the treatment of solid tumors. Participants with the following advanced solid tumors will be
Cohort 1: small cell lung cancer (SCLC) Cohort 2: non-small cell lung cancer-squamous
(NSCLC-squamous) Cohort 3: non-small cell lung cancer-nonsquamous (NSCLC-nonsquamous) Cohort
4: head and neck squamous cell carcinoma (HNSCC) Cohort 5: esophageal squamous cell carcinoma
(esophageal-squamous) Cohort 6: gastric and gastroesophageal junction (GEJ) adenocarcinoma
Cohort 7: castration-resistant prostate cancer (CRPC) Cohort 8: melanoma
Participants will continue to receive study treatment until disease progression, unacceptable
toxicity, investigator decision, consent withdrawal, study termination by the sponsor,
pregnancy, or death, whichever comes first.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.